Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 672 results for diabetes

  1. Diabetes: IFCC-HbA1c 58mmol/mol or less (IND165)

    This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 58 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM141

  2. Diabetes: admission rates (lower limb amputation) (IND47)

    This indicator covers admission rates due to lower limb amputations in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG65

  3. Diabetes: thyroid disease screening (children T1DM) (IND312)

    This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have been screened for thyroid disease in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  4. Diabetes: annual psychological assessment (children T2DM) (IND314)

    This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  5. Diabetes: annual psychological assessment (children T1DM) (IND313)

    This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  6. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

  7. Diabetes: IFCC-HbA1c 75mmol/mol or less (IND136)

    This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.

  8. Diabetes: NDH annual HbA1c or FPG test (IND172)

    This indicator covers the percentage of patients with non-diabetic hyperglycaemia who have had an HbA1c test or FPG test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM150

  9. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date: TBC

  10. Type 2 diabetes in adults. Patient decision aid on type 2 diabetes: agreeing my blood glucose (HbA1c) target

    1 Type 2 diabetes: agreeing my blood glucose (HbA1c) target Patient decision aid c NICE 2022. All rights reserved. Subject to Notice of...

  11. Diabetes: register including type (IND100)

    This indicator covers establishing and maintaining a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM41

  12. Diabetes: admission rates (MI) (IND42)

    This indicator covers admission rates due to myocardial infarction in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG60

  13. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

  14. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

  15. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC